{"pmid":32302437,"title":"Should SARS-CoV-2 influence immunosuppressive therapy for autoimmune blistering diseases?","text":["Should SARS-CoV-2 influence immunosuppressive therapy for autoimmune blistering diseases?","In this dramatic period where the whole world is affected by the outbreak of coronavirus disease 19 (COVID-19), scientific data relating to the causative virus SARS-CoV-2 as well as the subsequent therapeutic repercussions on the management of other diseases should be divulged in order to share as much information as possible among experts in a timely manner.","J Eur Acad Dermatol Venereol","Di Altobrando, Ambra","Patrizi, Annalisa","Bardazzi, Federico","32302437"],"abstract":["In this dramatic period where the whole world is affected by the outbreak of coronavirus disease 19 (COVID-19), scientific data relating to the causative virus SARS-CoV-2 as well as the subsequent therapeutic repercussions on the management of other diseases should be divulged in order to share as much information as possible among experts in a timely manner."],"journal":"J Eur Acad Dermatol Venereol","authors":["Di Altobrando, Ambra","Patrizi, Annalisa","Bardazzi, Federico"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32302437","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jdv.16491","keywords":["covid-19","sars-cov-2","blistering disorders","bullous disorders","immunosuppressive therapy"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664357978493419520,"score":8.233237,"similar":[{"pmid":32283134,"pmcid":"PMC7151539","title":"Highlights for management of patients with Autoimmune Liver Disease during COVID-19 pandemia.","text":["Highlights for management of patients with Autoimmune Liver Disease during COVID-19 pandemia.","J Hepatol","Lleo, Ana","Invernizzi, Pietro","Lohse, Ansgar W","Aghemo, Alessio","Carbone, Marco","32283134"],"journal":"J Hepatol","authors":["Lleo, Ana","Invernizzi, Pietro","Lohse, Ansgar W","Aghemo, Alessio","Carbone, Marco"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32283134","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jhep.2020.04.002","keywords":["Autoimmune hepatitis","Autoimmune liver diseases","Covid-19","immunosuppressive therapy"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664182200801689602,"score":77.878586},{"pmid":32301600,"title":"A review of initial data on pregnancy during the COVID-19 outbreak: implications for assisted reproductive treatments.","text":["A review of initial data on pregnancy during the COVID-19 outbreak: implications for assisted reproductive treatments.","The current outbreak of the novel 2019 coronavirus disease (COVID-19) started in China in December 2019 and has since spread to several other countries. On March 25, 2020, a total of 375,498 cases had been confirmed globally with 2,201 cases in Brazil, showing the urgency of reacting to this international public health emergency. While in most cases, mild symptoms are observed, in some cases the infection leads to serious pulmonary disease. As a result, the possible consequences of the COVID-19 outbreak for pregnant women and its potential effects on the management of assisted reproductive treatments, demand attention. In this review, we summarize the latest research progress related to COVID-19 epidemiology and the reported data of pregnant women, and discuss the current evidence of COVID-19 infections during pregnancy and its potential consequences for assisted reproductive treatments. Reported data suggest that symptoms in pregnant women are similar to those in other people, and that there is no evidence for higher maternal or fetal risks. However, considering the initial data and lack of comprehensive knowledge on the pathogenesis of SARS-CoV-2 during pregnancy, human reproduction societies have recommended postponing the embryo transfers and do not initiate new treatment cycles. New evidence must be considered carefully in order to adjust these recommendations accordingly at any time and to guide assisted reproductive treatments.","JBRA Assist Reprod","Monteleone, Pedro Aa","Nakano, Mayra","Lazar, Victor","Gomes, Alecsandra P","de, Hamilton Martin","Bonetti, Tatiana Cs","32301600"],"abstract":["The current outbreak of the novel 2019 coronavirus disease (COVID-19) started in China in December 2019 and has since spread to several other countries. On March 25, 2020, a total of 375,498 cases had been confirmed globally with 2,201 cases in Brazil, showing the urgency of reacting to this international public health emergency. While in most cases, mild symptoms are observed, in some cases the infection leads to serious pulmonary disease. As a result, the possible consequences of the COVID-19 outbreak for pregnant women and its potential effects on the management of assisted reproductive treatments, demand attention. In this review, we summarize the latest research progress related to COVID-19 epidemiology and the reported data of pregnant women, and discuss the current evidence of COVID-19 infections during pregnancy and its potential consequences for assisted reproductive treatments. Reported data suggest that symptoms in pregnant women are similar to those in other people, and that there is no evidence for higher maternal or fetal risks. However, considering the initial data and lack of comprehensive knowledge on the pathogenesis of SARS-CoV-2 during pregnancy, human reproduction societies have recommended postponing the embryo transfers and do not initiate new treatment cycles. New evidence must be considered carefully in order to adjust these recommendations accordingly at any time and to guide assisted reproductive treatments."],"journal":"JBRA Assist Reprod","authors":["Monteleone, Pedro Aa","Nakano, Mayra","Lazar, Victor","Gomes, Alecsandra P","de, Hamilton Martin","Bonetti, Tatiana Cs"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32301600","week":"202016|Apr 13 - Apr 19","doi":"10.5935/1518-0557.20200030","keywords":["covid-19","sars-cov-2","assisted reproduction","pregnancy"],"source":"PubMed","topics":["Treatment","Prevention"],"weight":1,"locations":["China","Brazil"],"countries":["China","Brazil"],"countries_codes":["CHN|China","BRA|Brazil"],"_version_":1664357978538508290,"score":73.38149},{"pmid":32300516,"pmcid":"PMC7160052","title":"Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times.","text":["Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times.","With the emergence of the novel coronavirus disease (COVID-19) viral pandemic, there is uncertainty whether biologic agents for psoriasis may place patients at a higher risk for infection or more severe disease course. This commentary offers patient counseling recommendations based on the current available evidence. While there are currently no specific data for psoriasis biologics and COVID-19, data are presented here from phase III clinical trials of psoriasis biologics on rates of upper respiratory infection, influenza, and serious infection. Overall these data reveal that on the whole, psoriasis biologics do not show major increases in infection risk compared to placebo during the course of these trials. However, as the COVID-19 virus is a novel pathogen that is associated with mortality in a subset of patients, a cautious approach is warranted. We discuss factors that may alter the benefit-risk ratio of biologic use during this time of COVID-19 outbreak. Ultimately, treatment decisions should be made on the basis of dialogue between patient and provider, considering each patient's individualized situation. Once this pandemic has passed, it is only a matter of time before a new viral disease reignites the same issues discussed here.","Dermatol Ther (Heidelb)","Brownstone, Nicholas D","Thibodeaux, Quinn G","Reddy, Vidhatha D","Myers, Bridget A","Chan, Stephanie Y","Bhutani, Tina","Liao, Wilson","32300516"],"abstract":["With the emergence of the novel coronavirus disease (COVID-19) viral pandemic, there is uncertainty whether biologic agents for psoriasis may place patients at a higher risk for infection or more severe disease course. This commentary offers patient counseling recommendations based on the current available evidence. While there are currently no specific data for psoriasis biologics and COVID-19, data are presented here from phase III clinical trials of psoriasis biologics on rates of upper respiratory infection, influenza, and serious infection. Overall these data reveal that on the whole, psoriasis biologics do not show major increases in infection risk compared to placebo during the course of these trials. However, as the COVID-19 virus is a novel pathogen that is associated with mortality in a subset of patients, a cautious approach is warranted. We discuss factors that may alter the benefit-risk ratio of biologic use during this time of COVID-19 outbreak. Ultimately, treatment decisions should be made on the basis of dialogue between patient and provider, considering each patient's individualized situation. Once this pandemic has passed, it is only a matter of time before a new viral disease reignites the same issues discussed here."],"journal":"Dermatol Ther (Heidelb)","authors":["Brownstone, Nicholas D","Thibodeaux, Quinn G","Reddy, Vidhatha D","Myers, Bridget A","Chan, Stephanie Y","Bhutani, Tina","Liao, Wilson"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32300516","week":"202016|Apr 13 - Apr 19","doi":"10.1007/s13555-020-00377-9","keywords":["biologics","covid-19","coronavirus","infection","pandemic","psoriasis","sars-cov-2"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664357978581499904,"score":66.83435},{"pmid":32303885,"title":"Summary of 20 tracheal intubation by anesthesiologists for patients with severe COVID-19 pneumonia: retrospective case series.","text":["Summary of 20 tracheal intubation by anesthesiologists for patients with severe COVID-19 pneumonia: retrospective case series.","SARS-CoV-2 pandemic is announced and it is very important to share our experience to the critical care community in the early stage. Urgent intubation team was organized by anesthesiologists and was dispatched upon request. We have retrospectively reviewed medical charts of 20 critically ill patients with Covid-19 pneumonia who required tracheal intubation from February 17 to March 19 in Wuhan No.1 hospital, China. We collected their demographics, vital signs, blood gas analysis before and after tracheal intubation, and 7-day outcome after tracheal intubation. Out of 20 patients, 90% were over 60 years old and 15 were with at least one comorbidity. All meet the indication for tracheal intubation announced by treatment expert group. We had successfully intubated all patients using personal protective equipment without circulatory collapse during tracheal intubation. During the observational period, none of 17 anesthesiologists were infected. Although intubation improved SPO2, reduced PaCO2 and blood lactate, seven of 20 patients died within 7-days after tracheal intubation. Non-survivors showed significantly lower SPO2 and higher PaCO2 and blood lactate compared to survivors. For those who are anticipated to deteriorate severe pneumonia with poor prognosis, earlier respiratory support with tracheal intubation may be advised to improve outcome.","J Anesth","Zhang, Li","Li, Jiyong","Zhou, Mingxing","Chen, Zhijun","32303885"],"abstract":["SARS-CoV-2 pandemic is announced and it is very important to share our experience to the critical care community in the early stage. Urgent intubation team was organized by anesthesiologists and was dispatched upon request. We have retrospectively reviewed medical charts of 20 critically ill patients with Covid-19 pneumonia who required tracheal intubation from February 17 to March 19 in Wuhan No.1 hospital, China. We collected their demographics, vital signs, blood gas analysis before and after tracheal intubation, and 7-day outcome after tracheal intubation. Out of 20 patients, 90% were over 60 years old and 15 were with at least one comorbidity. All meet the indication for tracheal intubation announced by treatment expert group. We had successfully intubated all patients using personal protective equipment without circulatory collapse during tracheal intubation. During the observational period, none of 17 anesthesiologists were infected. Although intubation improved SPO2, reduced PaCO2 and blood lactate, seven of 20 patients died within 7-days after tracheal intubation. Non-survivors showed significantly lower SPO2 and higher PaCO2 and blood lactate compared to survivors. For those who are anticipated to deteriorate severe pneumonia with poor prognosis, earlier respiratory support with tracheal intubation may be advised to improve outcome."],"journal":"J Anesth","authors":["Zhang, Li","Li, Jiyong","Zhou, Mingxing","Chen, Zhijun"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32303885","week":"202016|Apr 13 - Apr 19","doi":"10.1007/s00540-020-02778-8","keywords":["blood gas analysis","covid-19","sars-cov-2","tracheal intubation"],"source":"PubMed","topics":["Treatment","Prevention"],"weight":1,"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Lactic Acid"],"_version_":1664431720492957697,"score":66.42659},{"pmid":32271462,"title":"Inositol and pulmonary function. Could myo-inositol treatment downregulate inflammation and cytokine release syndrome in SARS-CoV-2?","text":["Inositol and pulmonary function. Could myo-inositol treatment downregulate inflammation and cytokine release syndrome in SARS-CoV-2?","The outbreak of Sars-CoV-2 (COVID-19) poses serious challenges to people's health worldwide. The management of the disease is mostly supportive, and respiratory failure from acute respiratory distress syndrome is the leading cause of death in a significant proportion of affected patients. Preliminary data point out that dramatic increase in IL-6 and subsequent cytokine release syndrome may account for the development of fatal interstitial pneumonia. Inhibition of IL-6 by blocking its specific receptor with monoclonal antibodies has been advocated as a promising attempt. Here we assess the potential utility of myo-Inositol, a polyol already in use for treating the newborn Respiratory Distress Syndrome, in downregulating the inflammatory response upon Sars-CoV-2 infection. Myo-Inositol proved to reduce IL-6 levels in a number of conditions and to mitigate the inflammatory cascade, while being devoid of any significant side effects. It is tempting to speculate that inositol could be beneficial in managing the most dreadful effects of Sars-CoV-2 infection.","Eur Rev Med Pharmacol Sci","Bizzarri, M","Lagana, A S","Aragona, D","Unfer, V","32271462"],"abstract":["The outbreak of Sars-CoV-2 (COVID-19) poses serious challenges to people's health worldwide. The management of the disease is mostly supportive, and respiratory failure from acute respiratory distress syndrome is the leading cause of death in a significant proportion of affected patients. Preliminary data point out that dramatic increase in IL-6 and subsequent cytokine release syndrome may account for the development of fatal interstitial pneumonia. Inhibition of IL-6 by blocking its specific receptor with monoclonal antibodies has been advocated as a promising attempt. Here we assess the potential utility of myo-Inositol, a polyol already in use for treating the newborn Respiratory Distress Syndrome, in downregulating the inflammatory response upon Sars-CoV-2 infection. Myo-Inositol proved to reduce IL-6 levels in a number of conditions and to mitigate the inflammatory cascade, while being devoid of any significant side effects. It is tempting to speculate that inositol could be beneficial in managing the most dreadful effects of Sars-CoV-2 infection."],"journal":"Eur Rev Med Pharmacol Sci","authors":["Bizzarri, M","Lagana, A S","Aragona, D","Unfer, V"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32271462","week":"202015|Apr 06 - Apr 12","doi":"10.26355/eurrev_202003_20715","source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["Inositol"],"_version_":1663620083136593920,"score":66.11784}]}